A number of firms have modified their ratings and price targets on shares of Tempus AI (NASDAQ: TEM) recently:
- 9/21/2026 – Tempus AI is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $75.00 price target on the stock.
- 9/21/2026 – Tempus AI is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $75.00 price target on the stock.
- 9/11/2026 – Tempus AI was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 9/11/2026 – Tempus AI had its price target raised by HC Wainwright from $56.00 to $66.00. They now have a “buy” rating on the stock.
- 9/9/2026 – Tempus AI is now covered by UBS Group AG. They set a “neutral” rating and a $70.00 price target on the stock.
- 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
- 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
- 9/8/2026 – Tempus AI is now covered by Roth Capital. They set a “neutral” rating and a $67.00 price target on the stock.
- 9/2/2026 – Tempus AI was given a new $80.00 price target by Raymond James Financial, Inc..
- 9/2/2026 – Tempus AI is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $80.00 price target on the stock.
- 9/1/2026 – Tempus AI was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $76.00 price target on the stock, up from $56.00.
- 8/27/2026 – Tempus AI was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 8/20/2026 – Tempus AI had its price target raised by BTIG Research from $70.00 to $80.00. They now have a “buy” rating on the stock.
- 8/12/2026 – Tempus AI was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 8/4/2026 – Tempus AI had its price target lowered by Piper Sandler from $58.00 to $56.00. They now have a “neutral” rating on the stock.
- 8/3/2026 – Tempus AI had its price target lowered by BTIG Research from $80.00 to $70.00. They now have a “buy” rating on the stock.
- 8/3/2026 – Tempus AI had its price target lowered by HC Wainwright from $64.00 to $56.00. They now have a “buy” rating on the stock.
- 8/3/2026 – Tempus AI had its price target lowered by Stifel Nicolaus from $60.00 to $50.00. They now have a “hold” rating on the stock.
- 7/31/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
Insiders Place Their Bets
In other Tempus AI news, CAO Ryan M. Bartolucci sold 7,062 shares of the business’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $529,650.00. Following the sale, the chief accounting officer directly owned 60,804 shares in the company, valued at approximately $4,560,300. The trade was a 10.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the transaction, the chief executive officer owned 15,874 shares of the company’s stock, valued at approximately $1,111,180. This represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,490,499 shares of company stock worth $92,463,782. 24.26% of the stock is owned by insiders.
Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.
The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.
Further Reading
- Five stocks we like better than Tempus AI
- Cintas Raises Guidance as a Major Catalyst Moves Closer
- 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
Receive News & Ratings for Tempus AI Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI Inc and related companies with MarketBeat.com's FREE daily email newsletter.
